Efficacy of a red yeast rice based nutraceutical in large subgroups of hypercholesterolemic subjects in every day clinical practice

  • A. F. G. Cicero
  • C. Benvenuti
  • ARMoweb study Group
Original Article


To verify the efficacy of a patented proprietary combination of nutraceuticals containing natural hypocholesterolemic and antioxidant agents as red yeast rice extract, policosanols, coenzyme Q10, astaxanthin, and folic acid in the following subgroups of hyperlipidemic subjects: fertile (F) versus menopause (M) women, adults versus elderly (>65 years), lunch versus dinner administration time. A randomised, multicenter study in 411 Italians units compared Armolipid-Rottapharm|Madaus (ARM) one tablet/day plus diet versus diet alone (D) for 16 weeks in hyperlipidemic patients [serum total cholesterol (tot-C) >200 mg/dL or LDL-cholesterol (LDL-C) >150 mg/dL at admission]. Efficacy parameters were measured at baseline and every 4 weeks. In 2,408 eligible subjects, 1,665 adults and 743 elderly, total and LDL-cholesterol were likewise reduced by ARM + D in both age classes and significantly versus D. In 1,246 cases, 302 F and 946 M, tot-C gradually and significantly decreased up to 18.7 and 16.8% in F and M treated groups versus 9% in D group. Similar reduction was observed in LDL-C. In 907 cases, the time of administration of ARM was detailed: 733 received ARM + D at dinner and 174 at lunch. Cholesterolemia improved equally in the two groups. The association of ARM with an appropriate diet is more effective than diet alone in reducing abnormal cholesterolemia, independently from age classes and administration time during the day, supporting its positive use for controlling hypercholesterolemia with a positive impact on CHD prevention in all categories of subjects.


Lipid-lowering agents Red yeast rice Diet Menopause Elderly Administration time 



We thank Ibis Informatica for the website and database realization and Angela Ponzoni for the logistic and organizing assistance to the project.

Conflict of interest

Dr. Benvenuti is Medical director of Rottapharm-Madaus that supported the study and produces the tested nutraceutical.


  1. 1.
    Preiss D, Sattar N (2009) Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clin Endocrinol 70(6):815–828CrossRefGoogle Scholar
  2. 2.
    Raza JA, Babb JD, Movahed A (2004) Optimal management of hyperlipidemia in primary prevention of cardiovascular disease. Int J Cardiol 97(3):355–366CrossRefGoogle Scholar
  3. 3.
    Cicero AFG, Derosa G, Bove M, Borghi C, Gaddi AV (2009) Long-term effectiveness and safety of a nutraceutical based approach to reduce cholesterolemia in statin intolerant subjects with and without metabolic syndrome. Curr Top Nutraceutical Res 7(3–4):121–126Google Scholar
  4. 4.
    Cicero AFG, Ertek S (2008) Natural sources of antidyslipidaemic agents: is there an evidence-based approach for their prescription? Med J Nutr Metab 1(2):85–93CrossRefGoogle Scholar
  5. 5.
    Setnikar I, Senin P, Rovati LC (2005) Antiatherosclerotic efficacy of policosanol, red yeast rice extract and astaxanthin in the rabbit. Arzneimittelforschung 55:312–317Google Scholar
  6. 6.
    Endo A (1988) Chemistry, biochemistry, and pharmacology of HMG-CoA reductase inhibitors. Klin Wochenschr 66:421–427CrossRefGoogle Scholar
  7. 7.
    Man RY, Lynn EG, Cheung F, Tsang PS OK (2002) Cholestin inhibits cholesterol synthesis and secretion in hepatic cells (HepG2). Mol Cell Biochem 233:153–158CrossRefGoogle Scholar
  8. 8.
    Heber D, Yip I, Ashely JM, Elashoff DA, Go VLW (1999) Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 69:231–236Google Scholar
  9. 9.
    Wang J, Lu Z, Chi J, Wang W, Su M, Kou W, Yu P, Yu L, Chen L, Zhu J-S, Chang J (1997) Multicenter clinical trial of the serum lipid-lowering effects of a Monascus purpureus (red yeast) rice preparation from traditional Chinese medicine. Curr Ther Res 58:964–978CrossRefGoogle Scholar
  10. 10.
    Gouni-Berthold I, Berthold HK (2002) Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 143:356–365CrossRefGoogle Scholar
  11. 11.
    Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, Morgan JM, Capuzzi DM (2008) Chinese Coronary Secondary Prevention Study Group, Li S Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 101(12):1689–1693CrossRefGoogle Scholar
  12. 12.
    Cicero AF, Rovati LC, Setnikar I (2007) Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. A single-blind clinical investigation. Arzneimittelforschung 57(1):26–30Google Scholar
  13. 13.
    Grigore L, Radaelli L, Maggi FM, Rovati L, Catapano AL (2004) Armolipid, a nutritional supplement, effectively reduces plasma total and LDL cholesterol in moderate hypercholesterolemia. In: Abstracts of XV International Symposium on Drugs Affecting Lipid Metabolism Meeting. Venice, 24–27 OctoberGoogle Scholar
  14. 14.
    Caputi AP, Benvenuti C, ARMoweb Study group (2008) Improving the diet efficacy in hypercholesterolemic subjects with red yeast rice plus policosanols. L’Internista 16:53–60Google Scholar
  15. 15.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285(19):2486–2497CrossRefGoogle Scholar
  16. 16.
    Chen ZY, Jiao R, Ma KY (2008) Cholesterol-lowering nutraceuticals and functional foods. J Agric Food Chem 56(19):8761–8773CrossRefGoogle Scholar
  17. 17.
    Kajinami K, Masuya H, Hoshiba Y, Takeda K, Sato R, Okabayashi M, Schaefer EJ (2005) Statin response and pharmacokinetics variants. Expert Opin Pharmacother 6(8):1291–1297CrossRefGoogle Scholar
  18. 18.
    Plakogiannis R, Cohen H (2007) Optimal low-density lipoprotein cholesterol lowering: morning versus evening statin administration. Ann Pharmacother 41:106–110Google Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • A. F. G. Cicero
    • 1
    • 3
  • C. Benvenuti
    • 2
  • ARMoweb study Group
  1. 1.GC Descovich Atherosclerosis and Metabolic Disease Study Center; Alma Mater StudiorumUniversity of BolognaBolognaItaly
  2. 2.Medical DepartmentRottapharm|Madaus SpAMonzaItaly
  3. 3.Atherosclerosis and Metabolic Diseases Research Unit, Internal Medicine, Aging and Kidney diseases Department, Sant’Orsola-Malpighi HospitalUniversity of BolognaBolognaItaly

Personalised recommendations